On Nov 12, major Wall Street analysts update their ratings for $Fortrea Holdings (FTRE.US)$, with price targets ranging from $25 to $30.
Barclays analyst Luke Sergott maintains with a hold rating, and maintains the target price at $25.
Evercore analyst Elizabeth Anderson CFA maintains with a hold rating, and adjusts the target price from $20 to $25.
TD Cowen analyst Charles Rhyee maintains with a hold rating, and maintains the target price at $25.
Baird analyst Eric Coldwell maintains with a buy rating, and adjusts the target price from $28 to $30.
Furthermore, according to the comprehensive report, the opinions of $Fortrea Holdings (FTRE.US)$'s main analysts recently are as follows:
Following the Q3 report, it's noted that Fortrea experienced a notable increase in bookings, attributed to widespread robustness in biotech and large pharmaceutical companies. This performance is seen as indicative of Fortrea's engagement with market segments that are relatively insulated from the broader biotech funding challenges and major pharmaceutical restructurings.
The firm noted that Fortrea's Q3 results displayed indications of progress, hinting at the company gaining better foresight into its upcoming opportunities.
Expectations are set for exceptional EPS growth and recovery, particularly in the second half of 2025. It is anticipated that the company will successfully navigate TSA and spin transitions at the beginning of 2025, which should lead to a resumption in revenue growth, cost leverage, and reductions in interest expenses.
Here are the latest investment ratings and price targets for $Fortrea Holdings (FTRE.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月12日，多家華爾街大行更新了$Fortrea Holdings (FTRE.US)$的評級，目標價介於25美元至30美元。
巴克萊銀行分析師Luke Sergott維持持有評級，維持目標價25美元。
Evercore分析師Elizabeth Anderson CFA維持持有評級，並將目標價從20美元上調至25美元。
TD Cowen分析師Charles Rhyee維持持有評級，維持目標價25美元。
貝雅分析師Eric Coldwell維持買入評級，並將目標價從28美元上調至30美元。
此外，綜合報道，$Fortrea Holdings (FTRE.US)$近期主要分析師觀點如下：
根據Q3報告顯示，Fortrea的預訂量顯著增加，歸因於生物科技和大型藥品公司普遍的強勁表現。這種表現被視爲Fortrea與市場相對隔離於更廣泛生物科技資金挑戰和大型藥品重組的部分之間的互動的指示。
該公司指出，Fortrea的Q3結果顯示出取得進展的跡象，暗示公司對即將到來的機會有更好的前瞻。
對2025年下半年特別是第二季度的出色每股收益增長和復甦，期望較高。預計該公司將成功應對2025年初的TSA和分拆轉型，這應該導致營業收入增長的恢復、成本槓桿效應和利息費用的降低。
以下爲今日4位分析師對$Fortrea Holdings (FTRE.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
